Transaction DateRecipientSharesTypePriceValue
30th December 2020Capital, Llc Ikarian520,291Open or private purchase$9.61$4,999,996.51
29th December 2020Charles Theuer1,000Open or private purchase$9.98$9,980.00
29th December 2020Mark C Wiggins997Open or private purchase$10.57$10,538.29
29th December 2020Mark C Wiggins3Open or private purchase$10.56$31.68
22nd December 2020Management Inc. Opaleye657Open or private purchase$5.19$3,412.98
22nd December 2020Management Inc. Opaleye15,900Open or private purchase$5.19$82,597.32
22nd December 2020Management Inc. Opaleye496,277Open or private purchase$8.06$3,999,992.62
21st December 2020Management Inc. Opaleye2,059Open or private purchase$5.24$10,787.92
21st December 2020Management Inc. Opaleye51,400Open or private purchase$5.24$269,305.16
18th December 2020Management Inc. Opaleye1,400Open or private purchase$5.31$7,437.64
Tracon Pharmaceuticals
Tracon Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types. The company was founded in 2004 and is headquartered in San Diego, CA.

Ticker: TCON
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1394319
Employees: 19
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags